You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

DUBLIN--(BUSINESS WIRE)--The "Catenin Beta 1 - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or 1-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 6 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Key Topics Covered: Introduction Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile BBI-801 - Drug Profile exisulind - Drug Profile Oligonucleotides for Hepatoblastoma - Drug Profile PRI-724 - Drug Profile PRP - Drug Profile Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile Small Molecule to Inhibit Beta Catenin for Colorectal Cancer - Drug Profile Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile Synthetic Peptide for Oncology - Drug Profile Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile WX-024 - Drug Profile Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones Appendix Companies Mentioned For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/o5hfvo

Answer: Catenin Beta 1 Pipeline Review, H2 2020 - ResearchAndMarkets.com